RLM.L Regulatory News (RLM)

PuriCore plc

("PuriCore" or the "Company")

May 14 2013

PuriCore (LSE: PURI), the water-based, clean technology company, today announces changes to the Board. Charles Spicer, a seasoned medical technology executive based in the UK, has been appointed Independent Non-Executive Director with effect from 1 June 2013. The Company also announces that James Walsh, PhD, has elected to step down from the board effective from 27 June 2013 due to the increasing constraints on his time.

Mr Spicer has more than 15 years of experience working with the healthcare sector and specifically the medtech segment. He advises medtech and life sciences companies on corporate strategy, M&A, and corporate finance. Mr Spicer is a Non-Executive Director of Aircraft Medical, Stanmore Implants, Ark Therapeutics Group plc, and XCounter AB. He is chair of the UK Department of Health's Invention for Innovation Funding Panel, a panel member on the UK Health Innovation Challenge Fund, and a member of the techMARK Advisory Group at the London Stock Exchange. Previously, Mr Spicer served as chief executive and a Director of MDY Healthcare plc, an AIM-quoted strategic investment company focused on medtech and prior to that as head of healthcare at Numis Securities and Nomura International.

The Company confirms that there is no additional information about Mr Spicer that the Company is required to disclose under paragraph 9.6.13(1) to (6) of the Listing Rules of the Financial Conduct Authority.

Michael Ashton, Executive Chairman, said:

"Charles offers PuriCore an extensive background in strategic and corporate finance specifically focused on medtech companies. We welcome his insight and contribution as we continue to grow our Health Sciences sector including our Endoscopy, Wound Care, Dermatology, and Dental businesses in the UK, the US, and rest of the world. We thank Jim Walsh for his dedication, service, and healthcare industry expertise, which has been tremendously valuable to the Board."

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. PuriCore's antimicrobial technology and complementary products are used principally in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. PuriCore's breakthrough wound therapy solution is used to treat chronic and acute wounds including diabetic ulcers and burns as well as atopic dermatitis as dermatologic treatment products. In the Food & Agriculture market, both Sterilox Fresh and FloraFresh provide savings to supermarket retailers in labour costs and improvements in inventory loss of fresh produce and floral products. In addition, the Company is progressing in its research and development programmes at Oxford University on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.